INFUSE: Rationale and design of a multi-center, open label, collaborative study to treat HRS-AKI with continuous terlipressin infusion

INFUSE: Rationale and design of a multi-center, open label, collaborative study to treat HRS-AKI with continuous terlipressin infusion

Background: Hepatorenal syndrome-acute kidney injury (HRS-AKI) carries significant morbidity and mortality among those with end-stage liver disease. Bolus terlipressin for treatment of HRS-AKI received FDA approval in September 2022. US implementation of terlipressin, however, is hindered by the pau...

Полное описание

Библиографические подробности
Главные авторы: Ethan Weinberg, Suditi Rahematpura, Stevan A. Gonzalez, Manhal J. Izzy, Douglas A. Simonetto, R. Todd Frederick, Raymond A. Rubin, Jade Ikahihifo-Bender, Maggie Harte, Grace Kim-Lee, Sherry Witkiewicz, William Tobin, Khurram Jamil, Zachary Fricker, K. Rajender Reddy
Формат: Статья
Язык:English
Опубликовано: Elsevier 2023-12-01
Серии:Contemporary Clinical Trials Communications
Предметы:
Decompensated cirrhosis
Portal hypertension
Ascites
Hepatorenal syndrome
Liver transplant
Online-ссылка:http://www.sciencedirect.com/science/article/pii/S2451865423001576

Internet

http://www.sciencedirect.com/science/article/pii/S2451865423001576

Схожие документы